Page 34 - Read Online

Zuo et al. Herpes simplex encephalitis in adults

swelling, coning and death and lumbar puncture is to be helpful in the future.
be avoided. [27]
On the biological front, mechanisms of virus latent
Other therapies infection/recurrence and analysis of viral gene
Supporting therapies are also very important for structure and function need to be further explored using
HSE patients to prevent a variety of complications, advanced technologies. This might be accelerated by
such as respiration or cardiac failure, fluid balance the development of molecular genetics approaches
disorders and deep vein thrombosis. For patients with that could draw attention to the genetic conditions of
increased intracranial pressure, neurointensive care susceptible populations.
unit management is essential. Clinicians in the UK
recommended that the management of HSE should Financial support and sponsorship
be a participatory process, which is co-produced by None.
health professionals, patients, and their families. [28]
Conflicts of interest
Unresolved issues in therapy There are no conflicts of interest.
One important issue to consider is whether it is safe to
stop acyclovir when the CSF PCR result is negative. Patient consent
The 2012 ABN guidelines recommend that aciclovir There is no patient involved.
might be stopped in immunocompetent patients, if:
(a) an alternative diagnosis has been made, or (b) Ethics approval
HSV PCR in the CSF is negative on two occasions This article does not contain any studies with human
in a 24-48 h period and MRI is not characteristic for participants or animals.
HSV encephalitis, or (c) HSV PCR in the CSF is
negative once after 72 h from neurological symptoms REFERENCES
appearance, with unaltered consciousness, normal
MRI (performed after 72 h from symptoms appearance) 1. Whitley RJ. Herpes simplex virus. In: Scheld WM, Whitley RJ,
and with white cell count in the CSF less than 5 × 10 /L Durack DT, editors. Infections of the central nervous system. 2nd ed.
6
(B, III). [3] Philadelphia: Lippincott-Raven; 1997. p. 73-89.
2. Granerod J, Ambrose HE, Davies NW, Clewley JP, Walsh AL, Morgan
D, Cunningham R, Zuckerman M, Mutton KJ, Solomon T, Ward KN,
Another issue to take into account is that the Lunn MP, Irani SR, Vincent A, Brown DW, Crowcroft NS; UK Health
combination of acyclovir with other antiherpetic drugs is Protection Agency (HPA) Aetiology of Encephalitis Study Group.
either synergistic or additive. A randomized controlled Causes of encephalitis and differences in their clinical presentations
study by The National Institute of Allergy and Infectious in England: a multicentre, population-based prospective study. Lancet
Diseases Collaborative Antiviral Study Group showed Infect Dis 2010;10:835-44.
that, following standard treatment with intravenous 3. Solomon T, Michael BD, Smith PE, Sanderson F, Davies NW, Hart IJ,
ACV for PCR-confirmed HSE, an additional 3-month Holland M, Easton A, Buckley C, Kneen R, Beeching NJ; National
course of oral VCV therapy did not provide additional Encephalitis Guidelines Development and Stakeholder Groups.
Management of suspected viral encephalitis in adults -- Association
benefit. [29] of British Neurologists and British Infection Association National
Guidelines. J Infect 2012;64:347-73.
Up to date, there is a common belief that no other 4. Aurelius E, Johansson B, Sköldenberg B, Forsgren M. Encephalitis in
drugs can replace ACV for the treatment of HSE and immunocompetent patients due to herpes simplex virus type 1 or 2 as
drug combinations are not recommended. determined by type-specific polymerase chain reaction and antibody
assays of cerebrospinal fluid. J Med Virol 1993;39:179-86.
PROSPECTS 5. Miller S, Mateen FJ, Aksamit AJ Jr. Herpes simplex virus 2 meningitis:
a retrospective cohort study. J Neurovirol 2013;19:166-71.
6. Sureka J, Jakkani RK. Clinico-radiological spectrum of bilateral
Although ACV treatment in HSE is very effective, patient temporal lobe hyperintensity: a retrospective review. Br J Radiol
mortality is still approximately 14-19% and 45-60% of the 2012;85:e782-92.
[29]
survivors suffer from neuropsychological sequelae. 7. Kennedy PG, Chaudhuri A. Herpes simplex encephalitis. J Neurol
On the other hand, viral resistance is also a potential Neurosurg Psychiatry 2002;73:237-8.
limitation of HSE therapy. 8. Whitley RJ, Gnann JW. Viral encephalitis: familiar infections and
emerging pathogens. Lancet 2002;359:507-13.
In this context, there is an urgent clinical need for 9. Kamei S. Cognitive impairment in patients with bacterial meningitis
and encephalitides. Brain Nerve 2016;68:317-27. (in Japanese)
new therapeutic methods which can result in better 10. Whitley RJ. Herpes simplex virus infections of the central nervous
clinical outcomes for HSE patients and can prevent system. Encephalitis and neonatal herpes. Drugs 1991;42:406-27.
viral reactivation or infection. New approaches, such 11. Soong SJ, Watson NE, Caddell GR, Alford CA Jr, Whitley RJ. Use
as TLR agonists, IL-1 antagonists or vaccines may of brain biopsy for diagnostic evaluation of patients with suspected
[30]
[31]
26 Neuroimmunology and Neuroinflammation ¦ Volume 4 ¦ February 20, 2017